Bradley Lang

About Bradley Lang

I am a creative, forward thinking translational neuroscientist discovering and developing novel drugs for neurological diseases and injuries. I am currently the VP of Research at Convelo, where I lead the Biology and Efficacy efforts for the discovery of novel small molecule therapeutics to accelerate remyelination. Manage a team of 6 highly trained Scientists/Senior Scientists/Directors. Implemented AI machine-learning image segmentation to greatly accelerate and expand SEM-based myelin analysis. Prior to joining Convelo, I was part of the team which launched Nervgen to advance a regenerative treatment for spinal cord injury and other neuro-degenerative diseases (AD). Nervgen was founded based upon the foundational science from my (and others) graduate work in the Jerry Silver laboratory at Case Western Reserve University. I am the inventor of Intracellular Sigma Peptide (Lang et al, Nature, 2015), the precursor of NVG-291, currently finishing P1 clinical trials. From 20••••20, I was an Executive in Residence at BioEnterprise, providing strategic, executive-management, fundraising and technical support to entrepreneurs/institutions. My primary focus was therapeutics, life-sciences and platforms. Prior to BioEnterpise, I was a regenerative medicine scientist at Athersys. I received a B.S. in Natural Sciences/Neuroscience from the University of Wisconsin and Doctorate in Neuroscience from Case Western Reserve University.

Experience

1. Vice President of Research

   Convelo Therapeutics, Inc

   Jun 2017 — Present · Cleveland, OH, US

   Convelo Therapeutics is developing a new class of medicines that unlock the regenerative capacity of the central nervous system.

Education

• University of Wisconsin-Madison

  B.S, Biology

  2003 — 2007

• University of wiscon

  Bachelor of Science - BS, Neurobiology and Neurosciences

  2003 — 2007

• Case Western Reserve University

  Doctor of Philosophy (PhD), Neurosciences

  2009 — 2014